Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 740 results for "sun pharma advanced research"

Hanmi Pharmaceuticals to Assign the Rights of the Indian Territory to Kinex as Part of the Orascovery Program Strategic Plan
AndhraNews.net

Pharma shares dip on profit bookings

Related to : Sun Pharma Advanced Research Company Ltd,Strides Arcolab Ltd,Natco Pharma Ltd,Ajanta Pharma Ltd Sun Pharma Advanced Research Company Ltd BSE 20 Mar 15 | 03:28 PM 470.70 -69.45 (-12.86%) NSE 20 Mar 15 | 03:20 PM 472.80 ... Smart Investor, 2 months ago
Pharma shares extend fall; CNX Pharma index down 3% Business Standard India, 1 month ago
Markets remain flat; pharma shares gain Smart Investor, 2 months ago

23 images for sun pharma advanced research

India Infoline, 19 hours ago
India Infoline, 3 weeks ago
India Infoline, 3 weeks ago
India Infoline, 1 month ago
USA.Gov, 1 day ago
Reuters, 14 hours ago
NDTV Profit, 1 month ago
Reuters India, 3 weeks ago
Sify, 1 month ago
Sify, 1 month ago
Rediff.com

Buy Sun Pharma Advanced Research Company: Sudarshan Sukhani

According to Sudarshan Sukhani of s2analytics.com, one can buy Sun Pharma Advanced Research Company.
 Money Control5 days ago Board of Sun Pharma Advanced Research Company approves rights issue  Capital Market2 weeks ago Sun Pharma Advanced Research Company to hold board meeting  Business Standard3 weeks ago Sun Pharma Advanced conviction bet: Mehraboon Irani  Money Control4 weeks ago
[x]  
Money Control

SPARC to raise funds up to Rs 250 crore through rights issue

Sun Pharma Advanced Research Company (SPARC) has received an approval for further issuance of equity shares of Re 1 each of the company, on rights basis to the shareholders of the company on such ratio and at such price and premium as may be decided ...
 Indian-Commodity2 weeks ago SPARC to raise Rs 250 crore through rights issue  Business Standard2 weeks ago Sun Pharma, SPARC up 9-10%; antiepileptic drug gets FDA nod  Money Control2 months ago

Sun Pharma Advanced Research declines on reporting net loss of Rs 9.40 crore in Q4

SENSEX 26982.56 457.58 1.67% NIFTY 8181.00 143.80 1.73% Industry: Medical/Healthcare Company Sun ...
 Finalaya.com3 weeks ago Sun Pharma Advanced Research reports net loss of Rs 9.40 crore in Q4  Finalaya.com3 weeks ago SPARC rises on receiving approval to raise funds up to Rs 250 crore  Finalaya.com2 weeks ago SPARC in green on receiving approval to raise funds up to Rs 250 crore  Indian-Commodity2 weeks ago
[x]  
India Infoline

SPARC board meets for rights issue

The Board of Sun Pharma Advanced Research Company will meet on Tuesday to consider an issue of equity shares of ₹1 each by way of a rights issue. The board, however, will not decide on the ratio of rights share entitlements, issue price or record ...
 Hindu Business Line2 weeks ago Sun Pharma Advanced Board to consider Right Issue  India Infoline3 weeks ago SPARC board to meet next week to consider fund raising  Business Standard3 weeks ago SPARC Board to consider Right Issue  India Infoline3 weeks ago

SPARC jumps on rights issue plan

Sun Pharma Advanced Research Company rose 2.71% to Rs 386.25 at 9:54 IST on BSE after the company said its board will meet on 12 May 2015 to consider rights issue of equity shares. The announcement was made after market hours yesterday, 7 May ...
 Capital Market3 weeks ago
Moneycontrol.com

Sun Pharma Advance Research net loss rises to Rs.9.40 crore in Q4

Sun Pharma Advanced Research Company (SPARC) has suffered setback during the fourth quarter ended March 2015 and its net loss increased sharply to Rs. 9.40 crore from Rs. 2.51 crore in the corresponding period of last year. The higher loss is due to ...
 PharmaBiz3 weeks ago SPARC net loss widens to Rs 9.40 crore in Q4  Economic Times3 weeks ago
[x]  
Business Standard

Sun Pharma Advanced Research hits new high; zooms 200% in 2015

The stock surged 19% to Rs 562, extending its 15% rally past two trading days, on USFDA nod for antiepileptic drug. SI Reporter | Mumbai March 9, 2015 Last Updated at 09:51 IST Shares of Sun Pharma Research Company (SPARC) has zoomed 19% to Rs 562, extending ...
 Business Standard2 months ago SPARC announces USFDA approval of ELEPSIA XRTM  Money Control2 months ago SPARC gets USFDA nod for its anti-epileptic drug ELEPSIA XR  Business Standard2 months ago

Sun Pharma firm value rises by Rs 1,000 crore

Shares of Sun Pharma advanced research company (Sparc) on Thursday settled with gains of 10 per cent, adding Rs 1,014.53 crore to its market capitalisation, after the company received approval from the US health regulator for new drug application. In two ...
 Asian Age2 months ago SPARC shares touch upper circuit; m-cap up by over Rs 1,000 cr  Business Standard2 months ago SPARC shares settle with 5 pc gain; mcap up by Rs 440-cr  Business Standard2 months ago
Moneycontrol.com

SPARC, Balkrishna to replace ING

Sun Pharma Advanced Research Co (SPARC) will replace ING Vysya Bank in the S&P BSE 200 index from April 16, the BSE said in a circular on Thursday. Balkrishna Industries will replace ING Vysya Bank in the BSE S&P 500 index. This follows the merger ...
 Hindu Business Line1 month ago BSE to drop ING Vysya Bank from BSE 200, BSE 500 indices  ZeeNews.com1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - sun pharma advanced research
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less